• Celularity posted a shareholder letter from founder, chairman, CEO Robert J. Hariri in the investor relations section:
• Letter outlines a strategic shift toward placental-derived cell therapies in longevity, citing selective biotech capital markets and the need to streamline operations.
• Highlights NexGel out-licensing of biomaterials commercial assets for up to $30 million; transaction eliminated nearly $13 million of recorded liabilities.
• Identifies cenplacel-L as the lead product; expects 2026 revenue growth mainly from physician adoption in Florida, supported by a collaboration with Fountain Life.
• Notes appointment of Rick Gonzalez as chief commercial officer; flags ongoing evaluation of CYNK-001 natural killer cells as a potential senoblative therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celularity Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606031615PRIMZONEFULLFEED9731503) on June 03, 2026, and is solely responsible for the information contained therein.